Let's review the charts.
Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
Eating up MDLZ on a dip toward $50 looks like a delicious move.
PANW's decline does not appear to be over.
The Brooklyn-based company has a worldwide opportunity to match rabid sellers with rabid buyers.
Did the Fed aid Microsoft? No, Microsoft aided Microsoft. J&J aided J&J. Procter aided Procter.
The retailer's shares are rising after reporting earnings, but the mixed indicators found in its charts make it questionable whether the rally can be sustained.
Why Citigroup's underperformance versus the S&P 500 and the XLF will likely continue.
Here's how traders and investors can play it.